Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Microchip Biotechnologies Inc.

This article was originally published in Start Up

Executive Summary

Even as next-generation sequencing technologies make their way to the market, improving the efficiency of sample prep at the front end of large-scale genome sequencing will continue to be a viable strategy for significantly driving down costs and in so doing, expand applications. That's the initial strategy of Microchip Biotechnologies, which is commercializing microfluidic technology originally developed in the lab of Richard Mathies at Berkeley.

You may also be interested in...



Next-generation Sequencing: Slowly Moving towards the $1,000 Genome

Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.

Science Matters: Targeting Heme Trafficking In A Variety Of Diseases

A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.

Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091204

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel